Autoantibody status, neuroradiological and clinical findings in children with acute cerebellitis.

BACKGROUND

Acute cerebellitis (AC) in children and adolescents is an inflammatory disease of the cerebellum due to viral or bacterial infections but also autoimmune-mediated processes.

OBJECTIVE

To investigate the frequency of autoantibodies in serum and CSF as well as the neuroradiological features in children with AC.

MATERIAL AND METHODS

Children presenting with symptoms suggestive of AC defined as acute/subacute onset of cerebellar symptoms and MRI evidence of cerebellar inflammation or additional CSF pleocytosis, positive oligoclonal bands (OCBs), and/or presence of autoantibodies in case of negative cerebellar MRI. Children fulfilling the above-mentioned criteria and a complete data set including clinical presentation, CSF studies, testing for neuronal/cerebellar and MOG antibodies as well as MRI scans performed at disease onset were eligible for this retrospective multicenter study.

RESULTS

36 patients fulfilled the inclusion criteria for AC (f:m = 14:22, median age 5.5 years). Ataxia was the most common cerebellar symptom present in 30/36 (83 %) in addition to dysmetria (15/36) or dysarthria (13/36). A substantial number of children (21/36) also had signs of encephalitis such as somnolence or seizures. In 10/36 (28 %) children the following autoantibodies (abs) were found: MOG-abs (n = 5) in serum, GFAPα-abs (n = 1) in CSF, GlyR-abs (n = 1) in CSF, mGluR1-abs (n = 1) in CSF and serum. In two further children, antibodies were detected only in serum (GlyR-abs, n = 1; GFAPα-abs, n = 1). MRI signal alterations in cerebellum were found in 30/36 children (83 %). Additional supra- and/or infratentorial lesions were present in 12/36 children, including all five children with MOG-abs. Outcome after a median follow-up of 3 months (range: 1 a 75) was favorable with an mRS ≤2 in 24/36 (67 %) after therapy. Antibody (ab)-positive children were significantly more likely to have a better outcome than ab-negative children (p = .022).

CONCLUSION

In nearly 30 % of children in our study with AC, a range of abs was found, underscoring that autoantibody testing in serum and CSF should be included in the work-up of a child with suspected AC. The detection of MOG-abs in AC does expand the MOGAD spectrum.

Informations de copyright

© 2023 Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.

Déclaration de conflit d'intérêts

Declaration of competing interest L. Quack: no. S. Glatter: no. A. Wegener-Panzer: no. B. Cleaveland: no. A. Bertolini: no. V. Endmayr: R. Seidl:no. E. Wendel: no. M. Schimmel: no. M. Baumann: M. Rauchenzauner: M. Pritsch: no. N. Boy: no. T. Muralter: no. G. Kluger:no. V. Kraus: no. S. Leiz:no. C. Loehr-Nilles: no. J.H. Kreth: no. S. Braig: no. S. Schilling: no. J. Kern: no. C. Blank: no. B. Tro Baumann: no. S. Vieth: no. M. Wallot: no. H. Ringl: no. C. Makoswski: speakers honoraria from Desitin, Esai, Danone, Roche. M. Breu: speaker honoraria from Sanofi Genzyme. M Reindl was supported by a research support from Euroimmun and Roche. The University Hospital and Medical University of Innsbruck (Austria, employer of Dr. Reindl) receives payments for antibody assays (MOG, AQP4, and other autoantibodies) and for MOG and AQP4 antibody validation experiments organized by Euroimmun (Lübeck, Germany). F. Leypoldt: Reports speaker's honoraria from Grifols, Biogen, Bayer, Roche and Teva, advisory board positions for Roche and Biogen. FL's institute performs commercial antibody testing without FL receiving any personal financial benefit. Höftberger: speaker's honoraria from Novartis and Biogen. The Medical University of Vienna (Austria; employer of Dr. Höftberger) receives payment for antibody assays and for antibody validation experiments organized by Euroimmun (Lübeck, Germany). K. Rostasy: Serves as consultant for Roche in Operetta II trial and received speaker's honoraria from Merck.